Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $1.2 million.

  • Contineum Therapeutics' Other Accumulated Expenses fell 1253.73% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 1253.73%. This contributed to the annual value of $3.2 million for FY2024, which is 10381.63% up from last year.
  • As of Q3 2025, Contineum Therapeutics' Other Accumulated Expenses stood at $1.2 million, which was down 1253.73% from $1.7 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Other Accumulated Expenses high stood at $3.2 million for Q4 2024, and its period low was $973000.0 during Q2 2024.
  • Its 3-year average for Other Accumulated Expenses is $1.8 million, with a median of $1.6 million in 2023.
  • As far as peak fluctuations go, Contineum Therapeutics' Other Accumulated Expenses skyrocketed by 10381.63% in 2024, and later plummeted by 1253.73% in 2025.
  • Contineum Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.5 million in 2023, then surged by 103.82% to $3.2 million in 2024, then tumbled by 62.81% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.7 million for Q2 2025, and $2.5 million during Q1 2025.